SI3182999T1 - Anti-lag3 antibodies and antigen-binding fragments - Google Patents

Anti-lag3 antibodies and antigen-binding fragments

Info

Publication number
SI3182999T1
SI3182999T1 SI201531525T SI201531525T SI3182999T1 SI 3182999 T1 SI3182999 T1 SI 3182999T1 SI 201531525 T SI201531525 T SI 201531525T SI 201531525 T SI201531525 T SI 201531525T SI 3182999 T1 SI3182999 T1 SI 3182999T1
Authority
SI
Slovenia
Prior art keywords
antigen
binding fragments
lag3 antibodies
lag3
antibodies
Prior art date
Application number
SI201531525T
Other languages
Slovenian (sl)
Inventor
Linda Liang
Laurence Fayadat-Dilman
Rene De Waal Malefyt
Gopalan Raghunathan
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53938468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3182999(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of SI3182999T1 publication Critical patent/SI3182999T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SI201531525T 2014-08-19 2015-08-17 Anti-lag3 antibodies and antigen-binding fragments SI3182999T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462039081P 2014-08-19 2014-08-19
US201562171319P 2015-06-05 2015-06-05
PCT/US2015/045481 WO2016028672A1 (en) 2014-08-19 2015-08-17 Anti-lag3 antibodies and antigen-binding fragments
EP15753877.8A EP3182999B1 (en) 2014-08-19 2015-08-17 Anti-lag3 antibodies and antigen-binding fragments

Publications (1)

Publication Number Publication Date
SI3182999T1 true SI3182999T1 (en) 2021-04-30

Family

ID=53938468

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201531525T SI3182999T1 (en) 2014-08-19 2015-08-17 Anti-lag3 antibodies and antigen-binding fragments

Country Status (40)

Country Link
US (6) US20170290914A1 (en)
EP (2) EP3834842A1 (en)
JP (3) JP2017532059A (en)
KR (2) KR102037197B1 (en)
CN (1) CN107001470B (en)
AP (1) AP2017009763A0 (en)
AU (3) AU2015305770B2 (en)
BR (1) BR112017003194B8 (en)
CA (2) CA2957275C (en)
CL (1) CL2017000311A1 (en)
CO (1) CO2017001558A2 (en)
CR (1) CR20170059A (en)
CY (1) CY1124252T1 (en)
DK (1) DK3182999T3 (en)
DO (1) DOP2017000047A (en)
ES (1) ES2857505T3 (en)
GE (1) GEP20227343B (en)
GT (1) GT201700034A (en)
HR (1) HRP20210372T1 (en)
HU (1) HUE053641T2 (en)
IL (2) IL297053A (en)
JO (1) JO3663B1 (en)
LT (1) LT3182999T (en)
MA (2) MA55347A (en)
MD (1) MD4716C1 (en)
MX (2) MX2017002230A (en)
MY (1) MY187262A (en)
NI (1) NI201700018A (en)
PE (1) PE20170288A1 (en)
PH (1) PH12017500297A1 (en)
PL (1) PL3182999T3 (en)
PT (1) PT3182999T (en)
RS (1) RS61559B1 (en)
SG (1) SG11201701090VA (en)
SI (1) SI3182999T1 (en)
TN (1) TN2017000025A1 (en)
TW (3) TWI698448B (en)
UA (2) UA119571C2 (en)
WO (1) WO2016028672A1 (en)
ZA (2) ZA201700956B (en)

Families Citing this family (233)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2535354B1 (en) 2007-06-18 2017-01-11 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
US9416132B2 (en) 2011-07-21 2016-08-16 Tolero Pharmaceuticals, Inc. Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
AU2014205086B2 (en) 2013-01-14 2019-04-18 Xencor, Inc. Novel heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
PT3081576T (en) 2013-12-12 2019-10-15 Jiangsu Hengrui Medicine Co Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
CR20160425A (en) 2014-03-14 2017-05-26 Novartis Ag ANTIBODY MOLECULES THAT JOIN LAG-3 AND USES OF THE SAME
AP2016009475A0 (en) 2014-03-28 2016-09-30 Xencor Inc Bispecific antibodies that bind to cd38 and cd3
CN108064242B (en) 2014-05-28 2022-10-21 阿吉纳斯公司 anti-GITR antibodies and methods of use thereof
TWI693232B (en) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
JO3663B1 (en) * 2014-08-19 2020-08-27 Merck Sharp & Dohme Anti-lag3 antibodies and antigen-binding fragments
CN107206071A (en) 2014-09-13 2017-09-26 诺华股份有限公司 The conjoint therapy of ALK inhibitor
US20170209574A1 (en) * 2014-10-03 2017-07-27 Novartis Ag Combination therapies
ES2952717T3 (en) 2014-10-14 2023-11-03 Novartis Ag Antibody molecules against PD-L1 and uses thereof
PE20171324A1 (en) 2014-11-26 2017-09-11 Xencor Inc HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
MX2017006918A (en) 2014-11-26 2018-01-25 Xencor Inc Heterodimeric antibodies that bind cd3 and cd38.
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
MY189692A (en) 2015-05-07 2022-02-26 Memorial Sloan Kettering Cancer Center Anti-ox40 antibodies and methods of use thereof
PT3303394T (en) 2015-05-29 2020-07-01 Ludwig Inst For Cancer Res Ltd Anti-ctla-4 antibodies and methods of use thereof
TWI773646B (en) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 Lag-3-binding molecules and methods of use thereof
MA42459A (en) * 2015-07-16 2018-05-23 Bioxcel Therapeutics Inc NEW APPROACH TO CANCER TREATMENT BY IMMUNOMODULATION
HUE056201T2 (en) 2015-07-30 2022-02-28 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
RU2729371C1 (en) 2015-10-02 2020-08-06 Ф. Хоффманн-Ля Рош Аг Bispecific antibodies specific to pd1 and tim3
TWI756187B (en) 2015-10-09 2022-03-01 美商再生元醫藥公司 Anti-lag3 antibodies and uses thereof
MX2018006477A (en) 2015-12-02 2018-09-03 Agenus Inc Antibodies and methods of use thereof.
EP3387013B1 (en) 2015-12-07 2022-06-08 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
TWI758267B (en) 2015-12-14 2022-03-21 美商宏觀基因股份有限公司 Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
CN109069570A (en) * 2015-12-16 2018-12-21 默沙东公司 Anti- LAG3 antibody and antigen-binding fragment
WO2017143451A1 (en) * 2016-02-26 2017-08-31 Western University Anti-cd11d antibodies and uses thereof
US11559510B2 (en) 2016-04-06 2023-01-24 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
TWI794171B (en) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-l1 inhibitors
TWI808055B (en) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-1 inhibitors
LT3458478T (en) * 2016-05-18 2021-02-10 Boehringer Ingelheim International Gmbh Anti pd-1 and anti-lag3 antibodies for cancer treatment
MA45123A (en) 2016-05-27 2019-04-10 Agenus Inc ANTI-TIM-3 ANTIBODIES AND THEIR METHODS OF USE
EP3468581A1 (en) 2016-06-13 2019-04-17 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
RU2767357C2 (en) 2016-06-14 2022-03-17 Ксенкор, Инк. Bispecific checkpoint inhibitors antibodies
RU2756236C2 (en) 2016-06-20 2021-09-28 Кимаб Лимитед Pd-l1 specific antibodies
BR112018076525A2 (en) 2016-06-20 2019-04-02 F-Star Beta Limited lag-3 binding members
ES2858091T3 (en) 2016-06-20 2021-09-29 F Star Therapeutics Ltd Binding molecules that bind to PD-L1 and LAG-3
KR102497259B1 (en) * 2016-06-23 2023-02-07 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 LAG-3 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
CA3029328A1 (en) 2016-06-28 2018-01-04 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
NL2017270B1 (en) * 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
WO2018034227A1 (en) * 2016-08-15 2018-02-22 国立大学法人北海道大学 Anti-lag-3 antibody
CN110088132B (en) 2016-08-17 2020-10-27 康姆普根有限公司 anti-TIGIT antibodies, anti-PVRIG antibodies, and combinations thereof
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
TWI801350B (en) * 2016-09-08 2023-05-11 日商第一三共股份有限公司 Antibodies for treating autoimmune diseases and method for producing the same
CN110023337B (en) * 2016-10-11 2024-01-05 艾吉纳斯公司 anti-LAG-3 antibodies and methods of use thereof
EP3526255A2 (en) 2016-10-13 2019-08-21 Symphogen A/S Anti-lag-3 antibodies and compositions
WO2018071919A1 (en) 2016-10-14 2018-04-19 Xencor, Inc. IL15/IL15Rα HETERODIMERIC FC-FUSION PROTEINS
AU2017347809A1 (en) * 2016-10-28 2019-05-09 Merck Sharp & Dohme Llc Purification process for removal of tyrosine sulfation antibody variants; purified compositions
AU2017359467A1 (en) 2016-11-09 2019-05-02 Agenus Inc. Anti-OX40 antibodies, anti-GITR antibodies, and methods of use thereof
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
AU2017373944B2 (en) 2016-12-07 2022-02-03 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
CN108204958A (en) * 2016-12-19 2018-06-26 伊缪泰普有限公司 binding assay
TW201837168A (en) * 2017-01-06 2018-10-16 美商艾歐凡斯生物治療公司 Expansion of tumor infiltrating lymphocytes (TILS) with tumor necrosis factor receptor superfamily (TNFRSF) agonists and therapeutic combinations of TILS and TNFRSF agonists
CN110291089B (en) 2017-01-17 2022-05-27 海帕瑞吉尼克斯股份有限公司 Protein kinase inhibitors for promoting liver regeneration or reducing or preventing liver cell death
AU2018219887A1 (en) 2017-02-08 2019-08-22 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201907208XA (en) 2017-02-10 2019-09-27 Regeneron Pharma Radiolabeled anti-lag3 antibodies for immuno-pet imaging
AU2018220736A1 (en) 2017-02-20 2019-09-05 Dragonfly Therapeutics, Inc. Proteins binding HER2, NKG2D and CD16
WO2018153340A1 (en) * 2017-02-22 2018-08-30 I-Mab Anti-lag-3 antibodies and uses thereof
ES2928718T3 (en) 2017-04-03 2022-11-22 Hoffmann La Roche Immunoconjugates of an anti-PD-1 antibody with a mutant IL-2 or with IL-15
KR102346336B1 (en) 2017-04-05 2022-01-04 에프. 호프만-라 로슈 아게 Bispecific antibodies that specifically bind to PD1 and LAG3
EP4112644A1 (en) 2017-04-05 2023-01-04 F. Hoffmann-La Roche AG Anti-lag3 antibodies
EA201992350A1 (en) 2017-04-05 2020-03-23 Симфоген А/С COMBINED MEDICINES AIMED AT PD-1, TIM-3 AND LAG-3
TWI796329B (en) 2017-04-07 2023-03-21 美商默沙東有限責任公司 Anti-ilt4 antibodies and antigen-binding fragments
AR111651A1 (en) 2017-04-28 2019-08-07 Novartis Ag CONJUGATES OF ANTIBODIES THAT INCLUDE TOLL TYPE RECEIVER AGONISTS AND COMBINATION THERAPIES
RU2019138507A (en) * 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. ANTIBODY AGAINST LAG3 AND JOINT ANTIBODY AGAINST LAG3 AND ANTIBODY AGAINST PD-1
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
WO2018208868A1 (en) * 2017-05-10 2018-11-15 Smet Pharmaceutical Inc Human monoclonal antibodies against lag3 and uses thereof
WO2018222722A2 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
EP4245375A3 (en) 2017-05-30 2023-12-06 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
HRP20231457T1 (en) 2017-05-30 2024-05-10 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
CN111032085A (en) * 2017-06-05 2020-04-17 昆士兰医学研究所理事会 Combination of an immune checkpoint antagonist and a RANK-L (NF-KB ligand) antagonist or bispecific binding molecules thereof for use in cancer treatment or prevention and uses thereof
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
JP2020524694A (en) 2017-06-22 2020-08-20 ノバルティス アーゲー IL-1β binding antibodies for use in the treatment of cancer
CN110785187B (en) 2017-06-22 2024-04-05 诺华股份有限公司 Antibody molecules against CD73 and uses thereof
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
US20200223924A1 (en) 2017-06-27 2020-07-16 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
IL271833B1 (en) 2017-07-06 2024-05-01 Merus Nv Antibodies that modulate a biological activity expressed by a cell
US10844121B2 (en) * 2017-07-13 2020-11-24 Nanjing Leads Biolabs Co., Ltd Antibodies binding LAG-3 and uses thereof
JP2020527572A (en) 2017-07-20 2020-09-10 ノバルティス アーゲー Anti-LAG-3 antibody dosage regimen and its use
CA3073733A1 (en) * 2017-08-30 2019-03-07 Phanes Therapeutics, Inc. Anti-lag-3 antibodies and uses thereof
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
CN112272563A (en) * 2017-11-08 2021-01-26 Xencor股份有限公司 Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
BR112020008888A2 (en) 2017-11-16 2020-10-20 Novartis Ag combination therapies
MA50900A (en) * 2017-11-17 2020-09-23 Merck Sharp & Dohme TRANSCRIT 3 SPECIFIC ANTIBODIES OF IMMUNOGLOBULIN TYPE (ILT3) AND THEIR USES
US20200371091A1 (en) 2017-11-30 2020-11-26 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
CN111741976A (en) 2017-12-19 2020-10-02 F星贝塔有限公司 FC-binding fragments comprising the PD-L1 antigen-binding site
KR20200100098A (en) 2017-12-19 2020-08-25 젠코어 인코포레이티드 Engineered IL-2 FC fusion protein
AU2018391217A1 (en) * 2017-12-22 2020-07-09 Jiangsu Hengrui Medicine Co., Ltd. LAG-3 antibody pharmaceutical composition and use thereof
WO2019129137A1 (en) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 Anti-lag-3 antibody and uses thereof
CN109970856B (en) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 anti-LAG-3 antibodies and uses thereof
WO2019129136A1 (en) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 Anti-pd-l1 antibody and uses thereof
CN109970857B (en) 2017-12-27 2022-09-30 信达生物制药(苏州)有限公司 anti-PD-L1 antibodies and uses thereof
TW201930591A (en) 2018-01-08 2019-08-01 瑞士商諾華公司 Immune-enhancing RNAs for combination with chimeric antigen receptor therapy
US11655295B2 (en) 2018-01-18 2023-05-23 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-LAG-3 antibody and use thereof
CN108085393B (en) * 2018-01-31 2020-06-02 青岛泱深生物医药有限公司 Renal clear cell carcinoma-related biomarker and application thereof
EP3746116A1 (en) 2018-01-31 2020-12-09 Novartis AG Combination therapy using a chimeric antigen receptor
WO2019148412A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
US20210363243A1 (en) * 2018-02-01 2021-11-25 Merck Sharp & Dohme Corp. Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody
MX2020008336A (en) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor.
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
GB201802573D0 (en) * 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
WO2019179365A1 (en) 2018-03-20 2019-09-26 WuXi Biologics Ireland Limited Novel anti-lag-3 antibody polypeptide
CN111918873A (en) 2018-03-27 2020-11-10 百时美施贵宝公司 Real-time monitoring of titre using UV signals
AU2019241350A1 (en) 2018-03-30 2020-07-30 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against LAG-3 and uses thereof
EP3778639A4 (en) * 2018-04-02 2021-06-09 Mab-Venture Biopharm Co., Ltd. Lymphocyte activation gene-3 (lag-3) binding antibody and use thereof
WO2019195408A1 (en) * 2018-04-03 2019-10-10 Dragonfly Therapeutics, Inc. Antibody variable domains targeting dll3, and use thereof
WO2019195623A2 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
KR20210003814A (en) 2018-04-18 2021-01-12 젠코어 인코포레이티드 TIM-3 targeting heterodimer fusion protein containing IL-15/IL-15Rα Fc-fusion protein and TIM-3 antigen binding domain
JP2021521784A (en) 2018-04-18 2021-08-30 ゼンコア インコーポレイテッド PD-1 targeted heterodimer fusion proteins containing IL-15 / IL-15RaFc fusion proteins and PD-1 antigen binding domains and their use
BR112020022371A2 (en) * 2018-05-03 2021-02-02 Shanghai Epimab Biotherapeutics Co., Ltd. high affinity antibodies to pd-1 and lag-3 and bispecific binding proteins produced from them
UY38247A (en) 2018-05-30 2019-12-31 Novartis Ag ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
KR20210016390A (en) 2018-06-01 2021-02-15 노파르티스 아게 Binding molecules for BCMA and uses thereof
US11192877B2 (en) 2018-07-10 2021-12-07 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AR116109A1 (en) 2018-07-10 2021-03-31 Novartis Ag DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
CA3107660A1 (en) 2018-07-26 2020-01-30 Bristol-Myers Squibb Company Lag-3 combination therapy for the treatment of cancer
WO2020038397A1 (en) * 2018-08-21 2020-02-27 I-Mab Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
US20210317214A1 (en) * 2018-09-13 2021-10-14 Merck Sharp & Dohme Corp. Combination therapy of a pd-1 antagonist and lag3 antagonist for treating patients with non-microsatellite instability-high or proficient mismatch repair colorectal cancer
WO2020072821A2 (en) 2018-10-03 2020-04-09 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
KR20210080437A (en) 2018-10-19 2021-06-30 브리스톨-마이어스 스큅 컴퍼니 Combination Therapy for Melanoma
WO2020089811A1 (en) 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody drug conjugates
US20210347889A1 (en) * 2018-11-05 2021-11-11 Merck Sharp & Dohme Corp. Dosing regimen of anti-lag3 antibody and combination therapy with anti-pd-1 antibody for treating cancer
CA3118144A1 (en) * 2018-11-07 2020-05-14 Merck Sharp & Dohme Corp. Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
KR20210099066A (en) 2018-12-04 2021-08-11 스미토모 다이니폰 파마 온콜로지, 인크. CDK9 inhibitors and polymorphs thereof for use as agents for the treatment of cancer
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP3898974A1 (en) 2018-12-21 2021-10-27 Onxeo New conjugated nucleic acid molecules and their uses
WO2020128613A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
US20200369762A1 (en) 2018-12-21 2020-11-26 Novartis Ag Use of il-1beta binding antibodies
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
CN113227138A (en) 2018-12-21 2021-08-06 诺华股份有限公司 Use of IL-1 beta binding antibodies
WO2020167990A1 (en) 2019-02-12 2020-08-20 Tolero Pharmaceuticals, Inc. Formulations comprising heterocyclic protein kinase inhibitors
US20220144807A1 (en) 2019-02-15 2022-05-12 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN113329792A (en) 2019-02-15 2021-08-31 诺华股份有限公司 Substituted 3- (1-oxoisoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
MX2021010390A (en) 2019-03-01 2021-11-17 Xencor Inc Heterodimeric antibodies that bind enpp3 and cd3.
JP2022525149A (en) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド Treatment of Acute Myeloid Leukemia (AML) with Venetoclax Failure
WO2020198077A1 (en) 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
WO2020216383A1 (en) * 2019-04-26 2020-10-29 Single Cell Technology, Inc. Anti-lag-3 antibodies
WO2020236667A1 (en) * 2019-05-17 2020-11-26 Gb006, Inc. Methods of treating cancer
AU2020279371A1 (en) * 2019-05-22 2021-12-23 Leidos, Inc. LAG 3 binding peptides
EP3973274A1 (en) 2019-05-23 2022-03-30 Bristol-Myers Squibb Company Methods of monitoring cell culture media
EP3976832A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
EP3977132A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Cell localization signature and combination therapy
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
US11529350B2 (en) 2019-07-03 2022-12-20 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
EP3999052A4 (en) * 2019-07-17 2023-08-09 Noxopharm Limited Immuno-oncology therapy using isoflavone compounds
WO2021021767A1 (en) * 2019-07-30 2021-02-04 Merck Sharp & Dohme Corp. Anti-pd-1/lag3/tigit trispecific antibodies and anti-pd-1/lag3 bispecific antibodies
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
JP2022548881A (en) 2019-09-18 2022-11-22 ノバルティス アーゲー ENTPD2 Antibodies, Combination Therapy and Methods of Using Antibodies and Combination Therapy
CN114450028A (en) 2019-09-22 2022-05-06 百时美施贵宝公司 Quantitative spatial profiling for LAG-3antagonist therapy
BR112022007376A2 (en) 2019-10-21 2022-07-05 Novartis Ag COMBINATION THERAPIES WITH VENETOCLAX AND TIM-3 INHIBITORS
TW202128191A (en) 2019-10-21 2021-08-01 瑞士商諾華公司 Tim-3 inhibitors and uses thereof
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
CN115942973A (en) 2019-11-08 2023-04-07 百时美施贵宝公司 LAG-3 antagonist therapy for melanoma
MX2022005034A (en) * 2019-11-11 2022-05-16 Cstone Pharmaceuticals Suzhou Co Ltd Pharmaceutical combination and use thereof.
US20230333090A1 (en) * 2019-12-20 2023-10-19 Merck Sharp & Dohme Llc Lag3 antagonist cell based potency assay
US20230056470A1 (en) 2019-12-20 2023-02-23 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
CN114980902A (en) 2020-01-17 2022-08-30 诺华股份有限公司 Combination comprising a TIM-3 inhibitor and a hypomethylated drug for the treatment of myelodysplastic syndrome or chronic myelomonocytic leukemia
KR20220131279A (en) * 2020-01-21 2022-09-27 상하이 헨리우스 바이오테크, 인크. Anti-LAG3 monoclonal antibody and its manufacturing method and application
WO2021154908A1 (en) * 2020-01-29 2021-08-05 Merck Sharp & Dohme Corp. Methods of separating host cell lipases from an anti-lag3 antibody production
WO2021158938A1 (en) 2020-02-06 2021-08-12 Bristol-Myers Squibb Company Il-10 and uses thereof
KR102245082B1 (en) * 2020-02-14 2021-04-26 단국대학교 천안캠퍼스 산학협력단 Two periodontal ligament progenitor cell surface specific IgG type monoclonal antibodies LG43, LG73 and uses thereof
EP4125870A1 (en) 2020-03-30 2023-02-08 Noxopharm Limited Methods for the treatment of inflammation associated with infection
WO2021217117A1 (en) * 2020-04-24 2021-10-28 Memorial Sloan Kettering Cancer Center Targeted therapy for the treatment & prevention of life-threatening complications of infection
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
CA3185657A1 (en) 2020-06-04 2021-12-09 Leidos, Inc. Immunomodulatory compounds
CN111808192B (en) * 2020-06-05 2022-02-15 北京天广实生物技术股份有限公司 Antibodies that bind LAG3 and uses thereof
TW202214857A (en) 2020-06-19 2022-04-16 法商昂席歐公司 New conjugated nucleic acid molecules and their uses
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
JP2023532768A (en) 2020-07-07 2023-07-31 バイオエヌテック エスエー RNA for treatment of HPV-positive cancer
EP4188947A2 (en) 2020-07-31 2023-06-07 Leidos, Inc. Lag3 binding peptides
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2022040482A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
MX2023002332A (en) 2020-08-28 2023-03-21 Bristol Myers Squibb Co Lag-3 antagonist therapy for hepatocellular carcinoma.
US20230303700A1 (en) 2020-08-31 2023-09-28 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
EP4204021A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
US20230374064A1 (en) 2020-10-05 2023-11-23 Bristol-Myers Squibb Company Methods for concentrating proteins
EP4232019A1 (en) 2020-10-23 2023-08-30 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
IL302569A (en) 2020-11-06 2023-07-01 Novartis Ag Cd19 binding molecules and uses thereof
WO2022109987A1 (en) * 2020-11-27 2022-06-02 Shanghai Benemae Pharmaceutical Corporation Novel anti-lag3 antibodies and methods of making and using the same
JP2024508207A (en) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ LTBR agonists in combination therapy against cancer
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
TW202237119A (en) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Alk-5 inhibitors and uses thereof
CN116514971B (en) * 2020-12-10 2023-10-27 北京东方百泰生物科技股份有限公司 anti-LAG-3 monoclonal antibody, antigen binding fragment thereof and application thereof
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (en) 2020-12-21 2022-12-01 德商拜恩迪克公司 Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
PE20240820A1 (en) 2020-12-28 2024-04-18 Bristol Myers Squibb Co COMPOSITIONS OF ANTIBODIES AND METHODS OF USE THEREOF
EP4267172A1 (en) 2020-12-28 2023-11-01 Bristol-Myers Squibb Company Subcutaneous administration of pd1/pd-l1 antibodies
US11845791B2 (en) * 2021-03-08 2023-12-19 Medimmune, Llc Antibodies directed against GDF-15
IL305736A (en) 2021-03-09 2023-11-01 Xencor Inc Heterodimeric antibodies that bind cd3 and cldn6
EP4305065A1 (en) 2021-03-10 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
BR112023019847A2 (en) 2021-03-29 2023-11-07 Juno Therapeutics Inc METHODS FOR DOSING AND TREATMENT WITH A COMBINATION OF A CHECKPOINT INHIBITOR THERAPY AND A CAR T CELL THERAPY
TW202304979A (en) 2021-04-07 2023-02-01 瑞士商諾華公司 USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
TW202309022A (en) 2021-04-13 2023-03-01 美商努法倫特公司 Amino-substituted heterocycles for treating cancers with egfr mutations
WO2022240741A1 (en) 2021-05-12 2022-11-17 Dana-Farber Cancer Institute, Inc. Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof
AR125874A1 (en) 2021-05-18 2023-08-23 Novartis Ag COMBINATION THERAPIES
CN115403670A (en) 2021-05-26 2022-11-29 安徽瀚海博兴生物技术有限公司 anti-CD40 antibodies and uses thereof
EP4370552A1 (en) 2021-07-13 2024-05-22 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
CN115611983A (en) 2021-07-14 2023-01-17 三优生物医药(上海)有限公司 CLDN18.2 binding molecules and uses thereof
AU2022331262A1 (en) * 2021-08-17 2024-04-04 Msd International Business Gmbh Inducible il-2 and pd-1/pd-l1 combination therapy
CA3233205A1 (en) * 2021-09-29 2023-04-06 Yu Xia Anti-lag3 antibody, pharmaceutical composition and use
TW202333802A (en) 2021-10-11 2023-09-01 德商拜恩迪克公司 Therapeutic rna for lung cancer
AU2022375806A1 (en) 2021-10-29 2023-12-14 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
WO2023072294A1 (en) * 2021-11-01 2023-05-04 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-lag3 antibodies
WO2023111203A1 (en) 2021-12-16 2023-06-22 Onxeo New conjugated nucleic acid molecules and their uses
WO2023147371A1 (en) 2022-01-26 2023-08-03 Bristol-Myers Squibb Company Combination therapy for hepatocellular carcinoma
WO2023161350A1 (en) 2022-02-24 2023-08-31 Io Biotech Aps Nucleotide delivery of cancer therapy
WO2023164638A1 (en) 2022-02-25 2023-08-31 Bristol-Myers Squibb Company Combination therapy for colorectal carcinoma
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
WO2023170606A1 (en) 2022-03-08 2023-09-14 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
WO2023173011A1 (en) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Transient expression of therapeutic proteins
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
CN114634574B (en) * 2022-04-18 2022-12-20 先进生物(苏州)有限公司 scFv antibody against B7H6, encoding gene and application thereof
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US778A (en) 1838-06-12 Thomas wright
US4946A (en) 1847-01-26 Improvement in carriage-wheels
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JP2532858B2 (en) 1985-04-01 1996-09-11 セルテツク リミテツド Transformed myeloma cell line
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
ATE87659T1 (en) 1986-09-02 1993-04-15 Enzon Lab Inc BINDING MOLECULES WITH SINGLE POLYPEPTIDE CHAIN.
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
WO1990006952A1 (en) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
FR2656800B1 (en) 1990-01-08 1992-05-15 Roussy Inst Gustave NEW PROTEINS PRODUCED BY HUMAN LYMPHOCYTES, DNA SEQUENCE ENCODING THESE PROTEINS AND PHARMACEUTICAL AND BIOLOGICAL APPLICATIONS.
US5976877A (en) 1990-01-08 1999-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0546073T3 (en) 1990-08-29 1998-02-02 Genpharm Int Production and use of transgenic, non-human animals capable of forming heterologous antibodies
ES2241710T3 (en) 1991-11-25 2005-11-01 Enzon, Inc. PROCEDURE TO PRODUCE MULTIVALENT PROTEINS FROM UNION TO ANTIGEN.
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
DK1589107T3 (en) 1992-08-21 2010-04-26 Univ Bruxelles Immunuglobulins without light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
ES2162863T3 (en) 1993-04-29 2002-01-16 Unilever Nv PRODUCTION OF ANTIBODIES OR FRAGMENTS (FUNCTIONALIZED) OF THE SAME DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF CAMELIDAE.
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
PT758383E (en) 1994-05-06 2007-05-31 Roussy Inst Gustave Lag-3 protein soluble polypeptide fractions, method of production, therapeutic composition and anti-idiotype antibody
US5532210A (en) 1994-06-08 1996-07-02 E. I. Du Pont De Nemours And Company High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP0843557B1 (en) 1995-07-21 2002-11-13 Applied Research Systems ARS Holding N.V. Methods for detecting, identifying, isolating, and selectively labelling and targeting th1 lymphocytes by means of the lag-3 protein
DE69735502T2 (en) 1996-11-28 2006-12-14 Applied Research Systems Ars Holding N.V. LAG-3 PROTEIN MUTANTS, THEIR EXPRESSION AND USE
PT941329E (en) 1996-11-29 2004-11-30 Applied Research Systems METHOD FOR PREVENTING REJECTION OF RIPES IN TRANSPLANTATION AND TO PRODUCE A HOST CELL FOR UNIVERSAL GENETIC THERAPY USING LYMPHOCYTE ACTIVATION (LAG-3)
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
CA2290485C (en) 1997-05-21 2008-08-05 Biovation Limited Method for the production of non-immunogenic proteins
EP0900841A1 (en) 1997-06-18 1999-03-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) LAG-3 splice variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
JP2002531466A (en) 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド Humanized antibodies to gamma interferon
PL209786B1 (en) 1999-01-15 2011-10-31 Genentech Inc Variant of mother polypeptide containing Fc region, polypeptide containing variant of Fc region with altered affinity of Fc gamma receptor binding (Fc R), polypeptide containing variant of Fc region with altered affinity of Fc gamma neonatal receptor binding (Fc Rn), composition, isolated nucleic acid, vector, host cell, method for obtaining polypeptide variant, the use thereof and method for obtaining region Fc variant
ES2420835T3 (en) 1999-04-09 2013-08-27 Kyowa Hakko Kirin Co., Ltd. Procedure to control the activity of immunofunctional molecules
WO2002000879A2 (en) 2000-06-28 2002-01-03 Glycofi, Inc. Methods for producing modified glycoproteins
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7795002B2 (en) 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
AU2001296962A1 (en) 2000-09-29 2002-04-08 Schering Corporation Pegylated interleukin-10
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
SE0103423D0 (en) 2001-10-12 2001-10-12 Astrazeneca Ab polymorphism
AU2003226356A1 (en) 2002-04-12 2003-10-27 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
AU2004217526B2 (en) 2003-02-28 2010-02-04 St. Jude Children's Research Hospital Inc. T cell regulation
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
PE20050925A1 (en) 2003-11-10 2005-11-29 Schering Corp RECOMBINANT ANTI-INTERLEUQUIN HUMANIZED ANTIBODY 10
DE602005022871D1 (en) 2004-06-07 2010-09-23 Univ Ramot METHOD FOR THE PASSIVE IMMUNIZATION AGAINST A DISEASE OR DISEASE DETERIENTED BY AMYLOID AGGREGATION WITH REDUCED NERVE IGNITION RISK
MX2009001620A (en) 2006-08-11 2009-02-23 Schering Corp Antibodies to il-17a.
US8232372B2 (en) 2006-12-14 2012-07-31 Schering Corp. Engineered anti-TSLP antibody
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US9244059B2 (en) * 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
EP2535354B1 (en) 2007-06-18 2017-01-11 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
AR072999A1 (en) * 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
EP2361095B1 (en) * 2008-11-25 2017-12-20 AlderBio Holdings LLC Antagonists of il-6 to raise albumin and/or lower crp
PE20120415A1 (en) * 2008-12-12 2012-05-09 Boehringer Ingelheim Int ANTI-IGF ANTIBODIES
EP2542590B2 (en) 2010-03-05 2020-04-01 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
CA2804550C (en) 2010-07-09 2021-01-05 Bionovion Holding B.V. Agonistic antibody to cd27
US9132281B2 (en) 2011-06-21 2015-09-15 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
KR20140058532A (en) 2011-06-30 2014-05-14 겐자임 코포레이션 Inhibitors of t-cell activation
CA2853809A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Method for preparing antibodies having improved properties
WO2013066765A1 (en) 2011-11-01 2013-05-10 Merck Sharp & Dohme Corp. Mutation of tup1 in glycoengineered yeast
GB201120527D0 (en) 2011-11-29 2012-01-11 Ucl Business Plc Method
CA2877286C (en) 2012-06-18 2023-05-16 Yale University Compositions and methods for diminishing an immune response
UY34887A (en) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
CA2874864C (en) 2012-08-14 2023-02-21 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
CN104884089A (en) 2012-08-21 2015-09-02 葛兰素集团有限公司 Compositions comprising a single variable domain and camostat mesylate (CM)
JP2015527358A (en) 2012-08-21 2015-09-17 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ A composition comprising an antibody and camostat mesylate (CM)
MX359532B (en) * 2012-12-24 2018-10-01 Abbvie Inc Prolactin receptor binding proteins and uses thereof.
CA2902831C (en) 2013-03-15 2023-04-25 Glaxosmithkline Intellectual Property Development Limited Anti-lag-3 binding proteins
EP3666886A1 (en) 2013-03-15 2020-06-17 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
WO2014163684A1 (en) 2013-04-03 2014-10-09 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
DK2992017T3 (en) 2013-05-02 2021-01-25 Anaptysbio Inc ANTIBODIES AGAINST PROGRAMMED DEATH-1 (PD-1)
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
AU2014296887A1 (en) 2013-08-02 2016-01-28 Aduro Biotech Holdings, Europe B.V. Combining CD27 agonists and immune checkpoint inhibition for immune stimulation
RS64268B1 (en) 2013-09-20 2023-07-31 Bristol Myers Squibb Co Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
AU2014346852A1 (en) 2013-11-05 2016-06-16 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
RU2714142C2 (en) 2013-11-05 2020-02-12 Бавариан Нордик А/С Combination therapy for treating cancer with poxvirus expressing tumour antigen and antagonist and/or agonist of immune checkpoint inhibitor
AU2014360273A1 (en) 2013-12-06 2016-06-02 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
CA2936244A1 (en) 2014-01-21 2015-07-30 Medimmune, Llc Compositions and methods for modulating and redirecting immune responses
DK3556775T3 (en) 2014-01-28 2022-01-03 Bristol Myers Squibb Co ANTI-LAG-3 ANTIBODIES FOR THE TREATMENT OF HEMATOLOGICAL MALIGNITIES
CR20160425A (en) 2014-03-14 2017-05-26 Novartis Ag ANTIBODY MOLECULES THAT JOIN LAG-3 AND USES OF THE SAME
TWI693232B (en) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
EP3160497A4 (en) 2014-06-27 2018-01-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Conjugates for immunotherapy
JO3663B1 (en) * 2014-08-19 2020-08-27 Merck Sharp & Dohme Anti-lag3 antibodies and antigen-binding fragments
KR20170106453A (en) 2015-01-29 2017-09-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Use of gating inhibitors and vaccines for their combination and immunotherapy
MA41463A (en) 2015-02-03 2017-12-12 Anaptysbio Inc ANTIBODIES DIRECTED AGAINST LYMPHOCYTE ACTIVATION GEN 3 (LAG-3)
TN2017000440A1 (en) 2015-04-17 2019-04-12 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
TWI773646B (en) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 Lag-3-binding molecules and methods of use thereof
AR105444A1 (en) 2015-07-22 2017-10-04 Sorrento Therapeutics Inc THERAPEUTIC ANTIBODIES THAT JOIN THE PROTEIN CODIFIED BY THE GENOPHYPE ACTIVATION GEN 3 (LAG3)
LT3317301T (en) 2015-07-29 2021-07-26 Novartis Ag Combination therapies comprising antibody molecules to lag-3
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies

Also Published As

Publication number Publication date
TW201938589A (en) 2019-10-01
TN2017000025A1 (en) 2018-07-04
GEP20227343B (en) 2022-01-25
CO2017001558A2 (en) 2017-07-19
UA127888C2 (en) 2024-02-07
IL250566B2 (en) 2023-03-01
NI201700018A (en) 2017-03-08
PH12017500297A1 (en) 2017-07-17
CL2017000311A1 (en) 2017-08-18
MA40476A (en) 2017-06-28
KR102037197B1 (en) 2019-10-28
US11207406B2 (en) 2021-12-28
TWI673286B (en) 2019-10-01
TW201920284A (en) 2019-06-01
MA40476B1 (en) 2021-03-31
MX2017002230A (en) 2017-05-09
MD4716C1 (en) 2021-05-31
JP2018183173A (en) 2018-11-22
US10898571B2 (en) 2021-01-26
IL297053A (en) 2022-12-01
AU2020230256B2 (en) 2024-01-18
US20190083614A1 (en) 2019-03-21
ES2857505T3 (en) 2021-09-29
MY187262A (en) 2021-09-16
CA3082655A1 (en) 2016-02-25
CY1124252T1 (en) 2022-07-22
RS61559B1 (en) 2021-04-29
DK3182999T3 (en) 2021-03-15
IL250566A0 (en) 2017-03-30
UA119571C2 (en) 2019-07-10
IL250566B (en) 2022-11-01
SG11201701090VA (en) 2017-03-30
US20190091332A1 (en) 2019-03-28
AU2018278910A1 (en) 2019-01-03
BR112017003194A2 (en) 2017-11-28
US20170290914A1 (en) 2017-10-12
DOP2017000047A (en) 2017-05-15
KR102321166B1 (en) 2021-11-02
MX2019005426A (en) 2023-04-27
HUE053641T2 (en) 2021-07-28
PL3182999T3 (en) 2021-05-31
BR112017003194B1 (en) 2020-06-09
US20190083615A1 (en) 2019-03-21
AP2017009763A0 (en) 2016-02-28
AU2015305770A1 (en) 2017-03-09
BR112017003194B8 (en) 2023-04-18
AU2015305770B2 (en) 2018-09-13
JP6538247B2 (en) 2019-07-03
MD20170031A2 (en) 2017-07-31
MA55347A (en) 2022-01-26
KR20170043589A (en) 2017-04-21
CN107001470B (en) 2021-06-22
CA2957275A1 (en) 2016-02-25
ZA201700956B (en) 2022-05-25
ZA202003742B (en) 2022-08-31
TW201613979A (en) 2016-04-16
KR20190122881A (en) 2019-10-30
CR20170059A (en) 2017-04-28
PE20170288A1 (en) 2017-04-05
GT201700034A (en) 2019-10-10
PT3182999T (en) 2021-03-01
LT3182999T (en) 2021-03-25
CN107001470A (en) 2017-08-01
MD4716B1 (en) 2020-10-31
EP3182999A1 (en) 2017-06-28
TWI698448B (en) 2020-07-11
CA2957275C (en) 2020-08-25
AU2020230256A1 (en) 2020-10-01
US10188730B2 (en) 2019-01-29
US11278620B2 (en) 2022-03-22
WO2016028672A1 (en) 2016-02-25
US20220257762A1 (en) 2022-08-18
US20170267759A1 (en) 2017-09-21
EP3182999B1 (en) 2021-01-06
HRP20210372T1 (en) 2021-07-09
JO3663B1 (en) 2020-08-27
TWI742395B (en) 2021-10-11
JP2019122405A (en) 2019-07-25
EP3834842A1 (en) 2021-06-16
JP6843174B2 (en) 2021-03-17
JP2017532059A (en) 2017-11-02

Similar Documents

Publication Publication Date Title
ZA202003742B (en) Anti-lag3 antibodies and antigen-binding fragments
HK1254953A1 (en) Anti-vista antibodies and fragments
HK1255067A1 (en) Anti-c10orf54 antibodies and uses thereof
HK1243440A1 (en) Anti-interleukin-33 antibodies and uses thereof
EP3399989A4 (en) Anti-lag3 antibodies and antigen-binding fragments
IL251537A0 (en) Humanized anti-ox40 antibodies and uses thereof
IL247407A0 (en) Anti-egfrviii antibodies and uses thereof
IL284291A (en) Humanized anti-acth antibodies and use thereof
IL251001B (en) Anti-il-25 antibodies and uses thereof
IL258924A (en) Humanized anti-dkk2 antibody and uses thereof